Trevi Therapeutics
TRVI
80 hedge funds and large institutions have $178M invested in Trevi Therapeutics in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 5 closing their positions.
340% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 5
300% more call options, than puts
Call options by funds: $8K | Put options by funds: $2K
153% more capital invested
Capital invested by funds: $70.2M → $178M (+$108M)
27% more funds holding
Funds holding: 63 → 80 (+17)
7.26% less ownership
Funds ownership: 82.03% → 74.77% (-7.3%)
41% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.91M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$2.99M |
| 3 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$580K |
| 4 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$446K |
| 5 |
SC
Shay Capital
New York
|
+$254K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Tejara Capital
London,
United Kingdom
|
-$2.75M |
| 2 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$2.09M |
| 3 |
CC
Checkpoint Capital
San Francisco,
California
|
-$1.75M |
| 4 |
Renaissance Technologies
New York
|
-$950K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$564K |
TRVI Hedge Fund Activity: Q1 2024 in Review
80 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q1 2024, worth a combined $178M — up 153% from $70.2M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TRVI positions and 5 closed out — a net gain of 17 holders — while 16 added to existing stakes and 27 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $4.91M. The largest seller was Tejara Capital, cutting an estimated $2.75M.
- 80 institutional investors held Trevi Therapeutics (TRVI) as of Q1 2024, up from 63 in Q4 2023.
- Funds reported $178M of Trevi Therapeutics stock for Q1 2024, up 153% quarter-over-quarter.
- 22 funds opened new Trevi Therapeutics positions in Q1 2024 and 5 closed out, a net change of +17 holders.
- The largest Trevi Therapeutics buyer in Q1 2024 was Logos Global Management, an estimated $4.91M added.
- The largest Trevi Therapeutics seller in Q1 2024 was Tejara Capital, an estimated $2.75M sold.
Based on aggregated 13F filings for Q1 2024.